4 mg/kg (DOX content) Tf-BMs-DOX was administered following intravenous injection, which allowed this nanotherapeutic to act systemically, and subsequently recognize and bind to cancer cells with high expression of TfR. This evidence concerns the gene TFRC and cancer.